

HARMONIZATION OF BIOLOGICS AND BIOSIMILAR REGULATIONS: EMERGING TRENDS, CHALLENGES, AND FUTURE PERSPECTIVES

¹Prashant Somwanshi

Research scholar

Department of Pharmaceutical Science

Asian International University Imphal West, Manipur, India

²Dr. Arvind Negi

Research Supervisor

Department of Pharmaceutical Science

Asian International University Imphal West, Manipur, India

ABSTRACT

The role of biologics and biosimilars in modern healthcare is significant, serving as crucial therapeutic tools for complex and chronic diseases, and enhancing accessibility and cost savings through biosimilars. Some regulatory differences remain, however, between countries regarding the selection of the reference product, analytical comparability, clinical and nonclinical data, interchangeability, pharmacovigilance and post approval requirements, which pose a challenge to international regulatory convergence. This current research explores future trends, key issues and prospects for the harmonization of biologics and biosimilar regulations. Narrative review and comparative regulatory analysis approach is used, following the regulatory guidelines, policy documents and published literature on various regulatory frameworks such as WHO, EMA, FDA, ICH and CDSCO. The review highlights analytical comparability, risk-based assessment, regulatory reliance, clinical and nonclinical requirements, interchangeability, pharmacovigilance, digital technologies and lifecycle management. The analysis shows that regulatory systems are shifting towards a scientific, risk-adapted, evidence-based approach with increased focus on the analytical characterization, totality-of-evidence assessment, reliance on regulation, collaborative assessment and lifecycle management. The study emphasises the need to collectively apply common scientific principles, regulatory cooperation, information sharing, work-sharing and reliance mechanisms to minimize unnecessary duplication and ensure adequate levels of quality, safety and efficacy.

Keywords: *Biologics; Biosimilars; Regulatory Harmonization; Regulatory Reliance; Interchangeability; Pharmacovigilance.*

1. INTRODUCTION

Biological medicines have revolutionized the way some of the most serious, complex and chronic diseases are managed, such as cancer, autoimmune diseases, diabetes and inflammatory diseases. Biologics are more complicated than conventional small molecule medicines, and they may have more complex structure, manufacturing processes, quality attributes and/or clinical evaluation. The emergence of biosimilars has presented a chance to address challenges to access to biological therapies and cost of treatment while ensuring quality, safety, and efficacy standards are met.



Figure 1: Harmonization

Although biosimilars are becoming more widely available, there are wide variations in regulatory requirements on a country by country and region by region basis. Adverse effects in the selection of the reference product, lack of analytical comparability, clinical evidence, interchangeability, pharmacovigilance and post-approval requirements can further complicate development and delay market access in other countries. Regulatory frameworks for the evaluation of biosimilars have been established by regulatory agencies including the World Health Organization (WHO), the European Medicines Agency (EMA), and the United States Food and Drug Administration (FDA) but remain challenging to converge globally due to the differences in how they implement their evaluation.

Thus harmonisation of biologics and biosimilar regulations has become an important field in pharmaceutical regulatory science. If scientific standards are converging more, reliance on regulations is growing, risk-based assessment is becoming more sophisticated, and collaborative regulatory processes are increasingly common, then there will be less duplication of effort without compromising patient safety. The current paper is based on a discussion of emerging trends, challenges and future perspectives on harmonization of biologics and biosimilar regulations, specifically a more uniform and scientifically sound global regulatory framework.

2. LITERATURE REVIEW

Kang et al. (2020) explored the overall regulatory environment of biosimilars and analyzed the work done by the World Health Organization (WHO) from 2009 to 2019. The study underscored the evolution of international regulations for biosimilar assessment, and advances toward harmonization of regulatory frameworks between countries. It highlighted the need of science-based regulatory assessment and convergence for the development and approval of biosimilars. The authors also discerned a number of remaining disparities between the national regulatory systems that require increased international cooperation and harmonization.

Ratih et al. (2021) conducted a review of the regulatory, manufacturing and analytical aspects of biosimilars and highlighted some aspects which go beyond their development and approval. The study discussed the complexity of biosimilar products and the importance of suitable analytical characterization, manufacturing controls, and regulatory aspects to establish similarity with the reference biological product. The authors noted that analytical and manufacturing techniques continued to improve in the development of biosimilars, making it more reliable, while regulatory expectations remained different and were still a hurdle for consistent evaluation and market access.

Joshi et al. (2022) reviewed the latest trends and regulatory status of biosimilars in oncology, where biological medicines had played an important role in the management of cancer. The study focused on the increasing development and use of oncology biosimilars, and outlined regulatory pathways for biosimilar approval and clinical use. The authors emphasized the need to provide the proper analytical, clinical and regulatory evidence to show biosimilarity. The review also noted that regulatory experience and the growing biosimilars in oncology had presented opportunities to enhance access to biological therapies while ensuring a high standard of quality, safety and efficacy.

3. METHODOLOGY

The present study employs a narrative review and comparative regulatory analysis method, which is based on literature, regulatory guidelines and policy documents published by WHO, EMA, FDA, ICH and CDSCO. The review concentrates on the evaluation of biosimilars, analytical comparability, clinical requirements, interchangeability, Pharmacovigilance, regulatory reliance, and lifecycle management to highlight key regulatory trends, challenges and opportunities for international harmonization.

4. GLOBAL REGULATORY FRAMEWORK FOR BIOLOGICS AND BIOSIMILARS

The worldwide regulatory system for biologics and biosimilars has been established to guarantee that biological medicines satisfy suitable high quality, safety, effectiveness, and consistency requirements. World Health Organization (WHO) guidelines offer international principles for the evaluation of biosimilars that include scientific and stepwise comparability approach. The European Medicines Agency (EMA) conducts a thorough comparison of biosimilars, which involves analytical and quality characterization and then suitable nonclinical and clinical evidence. The U.S. Food and Drug Administration (FDA) regulates biosimilars under the 351(k) pathway provided for by the Biologics Price Competition and Innovation Act, but has separate regulatory considerations for biosimilarity and interchangeability.




Figure 2: Biologics and Biosimilars

The International Council for Harmonisation (ICH) provides guidance to facilitate convergence of the regulatory environment with regard to the quality, safety, development, manufacture and life cycle management of biological products. The guidelines ICH Q5E, Q6B, Q9, Q10, and Q12 are examples of common scientific principles that can be applied to various regulatory systems. The Central Drugs Standard Control Organization (CDSCO) in India has laid down requirements for similar biologics and the subsequent developments have been directed towards its further alignment with international scientific and regulatory practices.

However, there are marked variations between different regulatory jurisdictions in the definition of interchangeability, clinical and nonclinical evidence, definition of reference-product, pharmacovigilance requirements, local requirements for clinical and nonclinical data, and post approval changes. The approach

of WHO is regulatory convergence and reliance, while the regional approach is more detailed by EMA and FDA according to their legal system.

Table 1: Comparative Overview of Major Biologics and Biosimilar Regulatory Frameworks

Regulatory Framework	Main Focus	Regulatory Approach	Key Characteristic
WHO	Biosimilar evaluation	Stepwise and science-based comparability	Promotes regulatory convergence and reliance
EMA	Biosimilar authorization	Comparative quality, nonclinical and clinical assessment	Established and comprehensive biosimilar assessment
FDA	Biosimilarity and interchangeability	351(k) pathway	Separate consideration of biosimilarity and interchangeability
ICH	Quality and lifecycle management	International technical guidelines	Provides common scientific principles
CDSCO, India	Similar biologics	Quality, safety, efficacy and comparability	Increasing alignment with international regulatory practices

As shown in Table 1, all the frameworks, namely, WHO, EMA, FDA, ICH, and CDSCO, share common principles of quality, safety, efficacy and scientific comparability. Their distinct regulatory pathways and requirements, however, vary significantly, especially in terms of biosimilarity, interchangeability and lifecycle management. The differences reflect the need for further convergence of international regulations.

5. EMERGING TRENDS IN BIOSIMILAR REGULATION AND HARMONIZATION

The regulation of biosimilars is now progressing to an internationally converged, science-based and risk adapted approach. The evaluation and monitoring of biosimilars is evolving due to advances in analytical technologies, experience gained from regulation, and global collaboration.

- **Analytical comparability:** The ability to make detailed comparisons of critical quality attributes like molecular structure, purity, glycosylation, aggregation and biological activity, using modern

analytical technologies. There is more use of analytical evidence, leading to a better determination of the degree of similarity and the scientific necessity of additional studies.

- **Risk-based regulatory assessment:** The regulators are increasingly taking into account the particulars and residual uncertainties of each biosimilar and are not applying the same requirements to each product. This can help to prevent unhelpful testing and ensure quality, safety and effectiveness.
- **Regulatory reliance and work-sharing:** Scientific evaluations by regulatory authorities based on assessment reports, and inspection information from trusted regulators, are increasing in use. Work-sharing can help to mitigate duplication, enhance regulatory capacity and facilitate quicker evaluation of biosimilars, especially in low-resource settings.
- **Reduction of unnecessary clinical studies:** Enhanced analytical characterization and pharmacokinetic/pharmacodynamic approaches are increasingly facilitating more targeted clinical development. For cases where the uncertainties are not addressed by analytical evidence, the scientific value of extensive comparative efficacy studies may not be needed.
- **Interchangeability:** Interchangeability is an area of great regulatory development. There are two different legal approaches, one for each EMA and FDA, both are based on scientific evidence of similarity, and clinical considerations. There should be greater international clarity on interchangeability and substitution to further minimize regulatory uncertainty.
- **Digital technologies and artificial intelligence:** Digital technologies and artificial intelligence are now becoming available as a possible support to help analyse complex analytical datasets, track manufacturing processes, detect signals within pharmacovigilance (PV) data and assist in regulatory decision-making. They will need to be appropriately validated, transparent, of good quality and supervised by humans.
- **Lifecycle management:** Regulatory aspects of biosimilars have begun to take a broader perspective of the product lifecycle, including manufacturing changes, quality monitoring, post approval safety, and process enhancements. International guidelines, e.g. ICH Q5E, ICH Q12, offer principles of biopharmaceutical management following the approval and of maintaining product quality over the product lifecycle.

6. CHALLENGES IN GLOBAL REGULATORY HARMONIZATION

Global harmonization of biologics and biosimilar regulations continues to face several challenges because regulatory systems differ in their scientific requirements, legal frameworks, and healthcare policies. The

time and costs of development and regulatory approval can be higher due to the differences in national requirements for quality assessment, clinical studies, approval process and post marketing monitoring. Another key problem is reference-product selection: in some countries only products approved locally will be used as reference products, while in others, products approved by foreign regulators will be used as reference products.

There is also the potential for duplication of studies, due to variations in clinical and nonclinical requirements, such as different expectations regarding animal studies, comparative efficacy studies, or pharmacokinetics and pharmacodynamics evaluation by the regulatory authorities. Another source of variation is interchangeability and substitution, where countries have different definitions and policies with regard to switching between reference products and biosimilars.

There are additional challenges with local data requirements in some jurisdictions, which may require local clinical or regulatory evidence. Biosimilar assessment may also be limited due to restricted regulatory capabilities in developing countries, including lack of specialized expertise, infrastructure, and financial resources. Lastly, issues of intellectual property, patent protection, exclusivity periods, reimbursement policies, and market access can impact the availability of biosimilars.

Table 2: Major Challenges in Global Biosimilar Regulatory Harmonization

Challenge	Description	Effect on Regulatory Harmonization
National regulatory differences	Countries may apply different approval and evidence requirements	Increases regulatory complexity
Reference-product selection	Requirements may differ for locally or internationally approved reference products	May create additional development requirements
Clinical and nonclinical requirements	Differences may exist in animal, PK/PD, and clinical evidence	Can result in duplication of studies
Interchangeability and substitution	Countries may apply different definitions and policies	Creates regulatory uncertainty

Pharmacovigilance and traceability	Safety monitoring and product identification systems may differ	Complicates international safety monitoring
Local data requirements	Some countries may require country-specific evidence	Increases development burden
Regulatory capacity	Some countries have limited technical expertise and infrastructure	May restrict effective regulatory assessment
Intellectual property and market access	Patents, exclusivity, reimbursement, and procurement policies vary	May influence biosimilar market entry

Some of the key challenges to global harmonization identified in Table 2 are the national requirements, selection of reference products, clinical and nonclinical evidence, interchangeability, pharmacovigilance, local data, and regulatory capacity. These differences can lead to higher level of duplication and complexity in biosimilar development, and impact on efficient market access throughout the world.

7. COMPARATIVE ANALYSIS AND PROPOSED HARMONIZATION FRAMEWORK

Although the scientific principles behind the regulatory approaches of WHO, EMA, FDA and specific national authorities are similar, there are different ways in which they are applied. WHO offers an international flexible framework for the evaluation of biosimilar products, EMA has a comparative approach for biosimilar assessment, and FDA has an established pathway for the assessment of the 351(k) biosimilars with a separate pathway for interchangeability. National regulatory authorities such as the CDSCO in India have established their own requirements and are increasingly taking into account international scientific advances. Such differences can be seen, in particular, with regard to the requirements for reference products, clinical evidence, interchangeability, and post-approval procedures.

There is a growing number of areas of regulatory convergence, such as more focus on analytical comparability, totality-of-evidence assessment, risk-based evaluation, pharmacovigilance, and lifecycle management. But there is still a wide gap in the acceptance of foreign reference products, needs for comparative clinical trials, local data, interchangeability, and substitution policies. Those differences can lead to higher duplication and complexity in the development of a biosimilar in a multinational context.

It is suggested that therefore, a proposed international harmonisation framework should include common scientific principles for reference-product selection, analytical characterisation, clinical and nonclinical evidence, pharmacovigilance and post-approval changes, with appropriately sized national flexibility.

Regulatory reliance and collaborative assessment may have a significant impact as it will allow the use of trusted regulatory evaluations, findings from inspections and scientific assessments carried out by other competent agencies. These can help to minimize duplication, boost regulatory capacity, and enable more efficient global access to safe, effective, and high quality biosimilars.

Table 3: Proposed Framework for International Harmonization of Biosimilar Regulations

Harmonization Area	Proposed Approach	Expected Outcome
Reference-product selection	Establish common principles for scientifically justified reference products	Reduces unnecessary duplication
Analytical comparability	Develop consistent expectations for critical quality attributes	Strengthens assessment of biosimilarity
Clinical and nonclinical evidence	Apply risk-based and targeted evidence requirements	Reduces scientifically unnecessary studies
Interchangeability	Promote clearer and more consistent scientific principles	Reduces regulatory uncertainty
Pharmacovigilance	Improve common safety-monitoring and traceability practices	Strengthens post-marketing surveillance
Regulatory reliance	Use trusted regulatory assessments and inspection findings	Reduces repeated regulatory work
Collaborative assessment	Encourage joint reviews and work-sharing	Strengthens regulatory capacity
Lifecycle management	Align principles for post-approval manufacturing changes	Supports consistent product quality

Table 3 outlines the main fields in which international harmonization can be enhanced. The unnecessary duplication of regulatory requirements can be minimised, with still sufficient standards of quality, safety and effectiveness, through common scientific standards, reliance on regulations, collaborative assessments, enhanced pharmacovigilance and harmonised lifecycle management.

8. DISCUSSION AND FUTURE PERSPECTIVES

Regulatory scientific consistency, regulatory efficiency, technology advancement and international collaboration will likely be key regulatory aspects for the future of biosimilar regulation. The key points of discussion and future development are:

- **Major Findings and Regulatory Convergence:** Biosimilar regulation is increasingly rooted in the principle of analytical comparability, risk-based assessment and totality of evidence, with some differences between national systems.
- **Implications for Regulators and Manufacturers:** Harmonized requirements and regulatory reliance can decrease duplication, make regulatory submission easier, and improve the efficiency of international biosimilar development.
- **Impact on Biosimilar Accessibility:** Efficient regulatory pathways can support faster availability of biosimilars, improve access to biological medicines, and encourage greater competition in the pharmaceutical market.
- **Future Regulatory Pathways:** Future strategies will focus on targeted clinical studies, pharmacokinetic/pharmacodynamic evidence, real-world evidence, and more reliance on regulatory reliance as a function of scientific uncertainty.
- **Advanced Analytical and Digital Technologies:** Advanced analytical approaches, digital tools and artificial intelligence can provide additional support to the product characterization, quality assessment, manufacturing monitoring and pharmacovigilance activities if properly validated.
- **Global Harmonization Opportunities:** Common scientific standards, harmonized terminology, information-sharing, collaborative assessments, and harmonized lifecycle-management practices can further promote global regulatory harmonization without compromising quality, safety, or efficacy.

9. CONCLUSION

The present study adopted a narrative review and comparative regulatory analysis approach to examine the harmonization of biologics and biosimilar regulations across different regulatory systems. WHO, EMA, FDA, ICH and CDSCO related regulatory guidelines, policy documents and published scientific literature pertaining to the development and evaluation of biosimilars were reviewed and relevant information was

collected. The review was particularly on analytical comparability, quality assessment, clinical and nonclinical evidence, interchangeability, pharmacovigilance, regulatory reliance, lifecycle management and post-approval requirements. The identified information was analysed thematically and comparatively to identify the elements of regulatory convergence and divergence, regulatory trends and main challenges for international harmonisation. The study also identified opportunities for common scientific standards, regulatory cooperation, work-sharing and reliance that could minimise unnecessary duplication of regulatory processes without compromising the quality, safety and efficacy of standards.

REFERENCES

1. Kang, H. N., Thorpe, R., Knezevic, I., Blades, C. D. R. Z., Levano, M. C., Chew, J. Y., ... & Yamaguchi, T. (2020). *The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. Biologicals*, 65, 1-9.
2. Ratih, R., Asmari, M., Abdel-Megied, A. M., Elbarbry, F., & El Deeb, S. (2021). *Biosimilars: Review of regulatory, manufacturing, analytical aspects and beyond. Microchemical Journal*, 165, 106143.
3. Joshi, D., Khursheed, R., Gupta, S., Wadhwa, D., Singh, T. G., Sharma, S., ... & Singh, S. K. (2022). *Biosimilars in oncology: latest trends and regulatory status. Pharmaceutics*, 14(12), 2721.
4. Nupur, N., Joshi, S., Gulliarme, D., & Rathore, A. S. (2022). *Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms. Frontiers in bioengineering and biotechnology*, 10, 832059.
5. Kang, H. N., Thorpe, R., Knezevic, I., Casas Levano, M., Chilufya, M. B., Chirachanakul, P., ... & Yamaguchi, T. (2021). *Regulatory challenges with biosimilars: an update from 20 countries. Annals of the New York Academy of Sciences*, 1491(1), 42-59.
6. Rathore, A. S., Stevenson, J. G., Chhabra, H., & Maharana, C. (2022). *The global landscape on interchangeability of biosimilars. Expert Opinion on Biological Therapy*, 22(2), 133-148.
7. Hock, S. C., Kian, S. M., & Wah, C. L. (2020). *Global challenges in the manufacture, regulation and international harmonization of GMP and quality standards for biopharmaceuticals. Generics and Biosimilars Initiative Journal*, 9(2), 52-64.
8. Oriama, R., Mudida, R., & Burger-Helmchen, T. (2022). *A multi-level perspective to biosimilars development: pathways towards incremental innovation in the health bioeconomy. In Transdisciplinarity (pp. 249-266). Cham: Springer International Publishing.*

9. Chhabra, H., Mouslim, M. C., Kashiramka, S., & Rathore, A. S. (2022). Dynamics of biosimilar uptake in emerging markets. *Expert Opinion on Biological Therapy*, 22(6), 679-688.
10. Gherghescu, I., & Delgado-Charro, M. B. (2020). The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. *Pharmaceutics*, 13(1), 48.
11. Rahalkar, H., Sheppard, A., Lopez-Morales, C. A., Lobo, L., & Salek, S. (2021). Challenges faced by the biopharmaceutical industry in the development and marketing authorization of biosimilar medicines in BRICS-TM countries: An exploratory study. *Pharmaceutical Medicine*, 35(4), 235-251.
12. Sciberras, J. (2020). Ethical and regulatory issues related to biosimilar medicines (Master's thesis, University of Malta).
13. Batran, R. A., Elmoshneb, M., Hussein, A. S., Hussien, O. M., Adel, F., Elgarhy, R., & Morsi, M. I. (2022). Biosimilars: science, implications, and potential outlooks in the Middle East and Africa. *Biologics: Targets and Therapy*, 161-171.
14. Gomes, I. D. S. A. (2020). Biosimilars in the Treatment of Inflammatory Bowel Disease: Current Trends and Future Perspectives (Master's thesis, Universidade de Lisboa (Portugal)).
15. Akram, M. S., Pery, N., Butler, L., Shafiq, M. I., Batoool, N., Rehman, M. F. U., ... & Yetisen, A. K. (2021). Challenges for biosimilars: focus on rheumatoid arthritis. *Critical reviews in biotechnology*, 41(1), 121-153.
16. Singh, M., & Solanki, P. R. (2022). An overview of legal and regulatory challenges of biological products. *Biomedical Product and Materials Evaluation*, 275-286.
17. Pouvkov, P. (2022). Generic and Biosimilar Medicines Industry—Opportunities and Challenges, Outlook and Sustainability. *The Membership of Bulgaria in the European Union: Fourteen Years Later*, 169-192.
18. Rahalkar, H. (2021). Evaluation of the Regulatory Requirements for Development and Approval of Biosimilar Medicines in the BRICS-TM Countries: Improving Patients' Access (Doctoral dissertation, University of Hertfordshire).
19. Teran, E., Gomez, H., Hanois, D., Lema, M., Mantilla, W., Rico-Restrepo, M., ... & Espinoza, M. A. (2022). Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. *The Lancet Oncology*, 23(7), e348-e358.
20. KERALLI, A. S., & SURESHKUMAR, R. (2020). Similar Biologics: Current Summary and Future Outlook. *International Journal of Pharmaceutical Research* (09752366), 12(4).